Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
Authors:
- David H AdamsDADavid H Adams
- Jeffrey J PopmaJPJeffrey J Popma
- Michael J ReardonMRMichael J Reardon
- 4 September 2014
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (10) , 967-968
Abstract
The pivotal U.S. CoreValve High Risk Study by Adams et al. (May 8 issue)1 clearly showed that the benefits of transcatheter aortic-valve replacement (TAVR) with the use of CoreValve (Medtronic) outweigh the harms, as compared with surgical aortic-valve replacement, in patients with severe aortic stenosis. The noninferiority criterion for the primary end point of mortality was met in the as-treated and intention-to-treat populations, and the result was robust with regard to missing data. However, the case for superiority was less clear. I estimate that only a few excess events in the TAVR group would have rendered the result nonsignificant; the one-sided P value calculated by means of the chi-square test is 0.053 for one excess event and 0.063 for two excess events.Keywords
This publication has 3 references indexed in Scilit:
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisNew England Journal of Medicine, 2014
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- Missing Data in the Regulation of Medical DevicesJournal of Biopharmaceutical Statistics, 2011